^
Association details:
| Biomarker: | PIK3CA mutation + ER mutation |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 4458: Clinical significance of PIK3CA and ESR1 mutations in ctDNA and FFPE samples from the MONARCH 2 study of abemaciclib plus fulvestrant
Excerpt:
The addition of abemaciclib to fulvestrant in MONARCH 2 demonstrated improvement in PFS regardless of PIK3CA or ESR1 status; however, the magnitude of benefit was numerically greater for patients with tumors harboring PIK3CA/ESR1 mutations.
Secondary therapy:
fulvestrant
DOI:
10.1158/1538-7445.AM2019-4458
